<unk>  (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.<unk>  belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda.  The North America rights to<unk>  are held by Elixir Pharmaceuticals.<unk>  has not yet gained FDA approval.
Mitiglinide
Liraglutide
Linagliptin
Exenatide
Vildagliptin
Saxagliptin
Sitagliptin
Ertugliflozin